Surrozen (NASDAQ:SRZN) Major Shareholder Group Gp Lp Column III Buys 12,470 Shares

Surrozen, Inc. (NASDAQ:SRZN) major shareholder Group Gp Lp Column III acquired 12,470 shares of Surrozen stock in a transaction that occurred on Tuesday, January 13th. The stock was acquired at an average cost of $19.80 per share, for a total transaction of $246,906.00. Following the purchase, the insider owned 996,502 shares of the company’s stock, valued at $19,730,739.60. The trade was a 1.27% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Large shareholders that own at least 10% of a company’s shares are required to disclose their sales and purchases with the SEC.

Group Gp Lp Column III also recently made the following trade(s):

• On Wednesday, January 14th, Group Gp Lp Column III bought 5,523 shares of Surrozen stock. The shares were bought at an average cost of $19.99 per share, with a total value of $110,404.77.
• On Tuesday, January 6th, Group Gp Lp Column III bought 15,100 shares of Surrozen stock. The shares were bought at an average cost of $19.89 per share, for a total transaction of $300,339.00.
• On Friday, December 5th, Group Gp Lp Column III purchased 30,884 shares of Surrozen stock. The stock was bought at an average price of $19.54 per share, for a total transaction of $603,473.36.
• On Thursday, December 4th, Group Gp Lp Column III acquired 5,266 shares of Surrozen stock. The shares were bought at an average price of $17.35 per share, with a total value of $91,365.10.
• On Thursday, November 13th, Group Gp Lp Column III acquired 315,457 shares of Surrozen stock. The stock was bought at an average cost of $12.65 per share, for a total transaction of $3,990,531.05.

Surrozen Stock Performance

SRZN stock remained flat at $20.00 during trading on Thursday. The company had a trading volume of 28,721 shares, compared to its average volume of 83,852. Surrozen, Inc. has a 1-year low of $5.90 and a 1-year high of $24.94. The stock has a 50 day moving average price of $18.38 and a 200-day moving average price of $13.80. The firm has a market cap of $171.40 million, a PE ratio of -0.90 and a beta of 0.58.

Surrozen (NASDAQ:SRZN) last issued its quarterly earnings results on Friday, November 7th. The company reported ($3.61) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.17) by ($2.44). Surrozen had a negative return on equity of 4,055.04% and a negative net margin of 2,909.10%.The firm had revenue of $0.98 million during the quarter. Equities analysts expect that Surrozen, Inc. will post -8.49 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

SRZN has been the subject of several research analyst reports. Weiss Ratings reissued a “sell (d-)” rating on shares of Surrozen in a research report on Wednesday, October 8th. Lifesci Capital upgraded Surrozen to a “strong-buy” rating in a report on Thursday, November 13th. Finally, Wall Street Zen raised Surrozen to a “sell” rating in a research note on Friday, November 28th. One investment analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Surrozen has an average rating of “Moderate Buy” and an average target price of $32.00.

Institutional Investors Weigh In On Surrozen

A number of hedge funds have recently added to or reduced their stakes in the company. Woodline Partners LP acquired a new position in Surrozen during the third quarter worth $621,000. Millennium Management LLC bought a new stake in shares of Surrozen during the third quarter worth about $1,414,000. Citadel Advisors LLC raised its holdings in shares of Surrozen by 32.8% in the 3rd quarter. Citadel Advisors LLC now owns 13,875 shares of the company’s stock worth $179,000 after acquiring an additional 3,424 shares during the last quarter. Schonfeld Strategic Advisors LLC acquired a new stake in shares of Surrozen in the 3rd quarter worth about $889,000. Finally, Acuta Capital Partners LLC lifted its position in Surrozen by 5.0% in the 3rd quarter. Acuta Capital Partners LLC now owns 178,415 shares of the company’s stock valued at $2,299,000 after acquiring an additional 8,415 shares in the last quarter. Institutional investors and hedge funds own 66.57% of the company’s stock.

About Surrozen

Surrozen, Inc is a clinical-stage biopharmaceutical company focused on developing novel therapeutic antibodies that target the Wnt signaling pathway for applications in tissue repair, regeneration and oncology. Founded in 2012 and headquartered in South San Francisco, California, the company leverages its proprietary SurroBody platform to design bispecific antibody molecules capable of modulating Wnt receptor activity with enhanced tissue specificity.

The SurroBody platform enables the generation of high-affinity, dual-binding antibodies engineered to either activate or inhibit Wnt signaling, a pathway critical to cell proliferation, differentiation and homeostasis.